Literature DB >> 28500078

A Time- and Compartment-Specific Activation of Lung Macrophages in Hypoxic Pulmonary Hypertension.

Steven C Pugliese1,2, Sushil Kumar1, William J Janssen2,3, Brian B Graham2, Maria G Frid1, Suzette R Riddle1, Karim C El Kasmi4, Kurt R Stenmark5.   

Abstract

Studies in various animal models suggest an important role for pulmonary macrophages in the pathogenesis of pulmonary hypertension (PH). Yet, the molecular mechanisms characterizing the functional macrophage phenotype relative to time and pulmonary localization and compartmentalization remain largely unknown. In this study, we used a hypoxic murine model of PH in combination with FACS to quantify and isolate lung macrophages from two compartments over time and characterize their programing via RNA sequencing approaches. In response to hypoxia, we found an early increase in macrophage number that was restricted to the interstitial/perivascular compartment, without recruitment of macrophages to the alveolar compartment or changes in the number of resident alveolar macrophages. Principal component analysis demonstrated significant differences in overall gene expression between alveolar and interstitial macrophages (IMs) at baseline and after 4 and 14 d hypoxic exposure. Alveolar macrophages at both day 4 and 14 and IMs at day 4 shared a conserved hypoxia program characterized by mitochondrial dysfunction, proinflammatory gene activation, and mTORC1 signaling, whereas IMs at day 14 demonstrated a unique anti-inflammatory/proreparative programming state. We conclude that the pathogenesis of vascular remodeling in hypoxic PH involves an early compartment-independent activation of lung macrophages toward a conserved hypoxia program, with the development of compartment-specific programs later in the course of the disease. Thus, harnessing time- and compartment-specific differences in lung macrophage polarization needs to be considered in the therapeutic targeting of macrophages in hypoxic PH and potentially other inflammatory lung diseases.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28500078      PMCID: PMC5501258          DOI: 10.4049/jimmunol.1601692

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension.

Authors:  Eleni Vergadi; Mun Seog Chang; Changjin Lee; Olin D Liang; Xianlan Liu; Angeles Fernandez-Gonzalez; S Alex Mitsialis; Stella Kourembanas
Journal:  Circulation       Date:  2011-04-25       Impact factor: 29.690

Review 2.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

3.  Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.

Authors:  Yi Jin; Thomas J Calvert; Bernadette Chen; Louis G Chicoine; Mandar Joshi; John Anthony Bauer; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

4.  Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer.

Authors:  Joanna M Poczobutt; Subhajyoti De; Vinod K Yadav; Teresa T Nguyen; Howard Li; Trisha R Sippel; Mary C M Weiser-Evans; Raphael A Nemenoff
Journal:  J Immunol       Date:  2016-02-12       Impact factor: 5.422

5.  Decreased alveolar oxygen induces lung inflammation.

Authors:  C Madjdpour; U R Jewell; S Kneller; U Ziegler; R Schwendener; C Booy; L Kläusli; T Pasch; R C Schimmer; B Beck-Schimmer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-10-11       Impact factor: 5.464

6.  Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Romy B Christmann; Everett Hayes; Sarah Pendergrass; Cristina Padilla; Giuseppina Farina; Alsya J Affandi; Michael L Whitfield; Harrison W Farber; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2011-06

7.  CCR5 as a treatment target in pulmonary arterial hypertension.

Authors:  Larissa Lipskaia; Shariq Abid; Lucie Poupel; Valérie Amsellem; Amal Houssaini; Rozenn Quarck; Elisabeth Marcos; Nathalie Mouraret; Aurélien Parpaleix; Régis Bobe; Guillaume Gary-Bobo; Mirna Saker; Jean-Luc Dubois-Randé; Mark T Gladwin; Karen A Norris; Marion Delcroix; Christophe Combadière; Serge Adnot
Journal:  Circulation       Date:  2014-07-03       Impact factor: 29.690

Review 8.  mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.

Authors:  Elena A Goncharova
Journal:  FASEB J       Date:  2013-01-25       Impact factor: 5.191

9.  Plasmid-based short hairpin RNA against connective tissue growth factor attenuated monocrotaline-induced pulmonary vascular remodeling in rats.

Authors:  R Wang; S-j Zhou; D-s Zeng; R Xu; L-m Fei; Q-q Zhu; Y Zhang; G-y Sun
Journal:  Gene Ther       Date:  2014-07-31       Impact factor: 5.250

10.  Evidence for the involvement of type I interferon in pulmonary arterial hypertension.

Authors:  Peter M George; Eduardo Oliver; Peter Dorfmuller; Olivier D Dubois; Daniel M Reed; Nicholas S Kirkby; Nura A Mohamed; Frederic Perros; Fabrice Antigny; Elie Fadel; Benjamin E Schreiber; Alan M Holmes; Mark Southwood; Guy Hagan; Stephen J Wort; Nathan Bartlett; Nicholas W Morrell; John G Coghlan; Marc Humbert; Lan Zhao; Jane A Mitchell
Journal:  Circ Res       Date:  2013-12-13       Impact factor: 17.367

View more
  36 in total

1.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

Review 2.  The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Authors:  Chen-Shan Chen Woodcock; Stephen Y Chan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-02-17       Impact factor: 2.457

3.  Nonclassical Monocytes Sense Hypoxia, Regulate Pulmonary Vascular Remodeling, and Promote Pulmonary Hypertension.

Authors:  Yen-Rei A Yu; Yuryi Malakhau; Chen-Hsin A Yu; Stefan-Laural J Phelan; R Ian Cumming; Matthew J Kan; Lan Mao; Sudarshan Rajagopal; Claude A Piantadosi; Michael D Gunn
Journal:  J Immunol       Date:  2020-01-29       Impact factor: 5.422

4.  An Hb-mediated circulating macrophage contributing to pulmonary vascular remodeling in sickle cell disease.

Authors:  Katherine Redinus; Jin Hyen Baek; Ayla Yalamanoglu; Hye Kyung H Shin; Radu Moldova; Julie W Harral; Delaney Swindle; David Pak; Scott K Ferguson; Rachelle Nuss; Kathryn Hassell; Eva Nozik-Grayck; Andre F Palmer; Mehdi A Fini; Vijaya Karoor; Kurt R Stenmark; Paul W Buehler; David C Irwin
Journal:  JCI Insight       Date:  2019-08-08

5.  Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension.

Authors:  Cheng-Jun Hu; Jens M Poth; Hui Zhang; Amanda Flockton; Aya Laux; Sushil Kumar; Brittany McKeon; Gary Mouradian; Min Li; Suzette Riddle; Steven C Pugliese; R Dale Brown; Eli M Wallace; Brian B Graham; Maria G Frid; Kurt R Stenmark
Journal:  Eur Respir J       Date:  2019-12-12       Impact factor: 16.671

6.  Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation.

Authors:  Gareth R Willis; Angeles Fernandez-Gonzalez; Jamie Anastas; Sally H Vitali; Xianlan Liu; Maria Ericsson; April Kwong; S Alex Mitsialis; Stella Kourembanas
Journal:  Am J Respir Crit Care Med       Date:  2018-01-01       Impact factor: 21.405

Review 7.  Origin and production of inflammatory perivascular macrophages in pulmonary hypertension.

Authors:  Jonathan Florentin; Partha Dutta
Journal:  Cytokine       Date:  2017-08-30       Impact factor: 3.861

8.  Interstitial macrophage-derived thrombospondin-1 contributes to hypoxia-induced pulmonary hypertension.

Authors:  Rahul Kumar; Claudia Mickael; Biruk Kassa; Linda Sanders; Daniel Hernandez-Saavedra; Daniel E Koyanagi; Sushil Kumar; Steve C Pugliese; Stacey Thomas; Jazalle McClendon; James P Maloney; William J Janssen; Kurt R Stenmark; Rubin M Tuder; Brian B Graham
Journal:  Cardiovasc Res       Date:  2020-10-01       Impact factor: 10.787

9.  Inflammatory Macrophage Expansion in Pulmonary Hypertension Depends upon Mobilization of Blood-Borne Monocytes.

Authors:  Jonathan Florentin; Emilie Coppin; Sathish Babu Vasamsetti; Jingsi Zhao; Yi-Yin Tai; Ying Tang; Yingze Zhang; Annie Watson; John Sembrat; Mauricio Rojas; Sara O Vargas; Stephen Y Chan; Partha Dutta
Journal:  J Immunol       Date:  2018-04-09       Impact factor: 5.422

10.  Consequences of Hypoxia for the Pulmonary Alveolar Epithelial Cell Innate Immune Response.

Authors:  Anne Sturrock; Diana Woller; Andrew Freeman; Karl Sanders; Robert Paine
Journal:  J Immunol       Date:  2018-10-31       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.